Comment
Author: Admin | 2025-04-28
Antimalarials to save lives We discover, develop and deliver malaria medicines tailored to the populations they serve. 22nd Call for compounds is open! Help develop the next generation of antimalarials to address drug resistance. To advance our drug discovery pipeline, MMV is welcoming proposals for compounds addressing key prevention, treatment and elimination needs.Deadline: 28 February 2025 Latest news and views MMV was formed as a product development partnership (PDP) 25 years ago in response to antimalarial drug resistance – the drugs were failing to treat the disease. Together with our partners, we’ve come a long way in developing and delivering new antimalarials and saving more lives, but the fight against malaria is still a race against resistance. Today, we continue innovating and developing new ways to stay one step ahead of the malaria parasite while progressing towards the global goal of zero malaria deaths. MMV's strategy to 2030 Explore the business plan to cure, prevent and eliminate malaria. Upcoming events The 8th edition of the SMC Alliance meeting will bring together stakeholders in the SMC community to exchange insights, celebrate successes and strengthen efforts to protect millions of vulnerable children from malaria. The Africa Health Agenda International Conference 2025, set for 2–5 March at the Kigali Convention Center, will unite innovation, community and global expertise to inspire actionable progress in Africa's health landscape. International Women's Day 2025, themed "Accelerate Action," celebrates women's achievements, raises awareness and drives efforts toward gender equality. Drug Discovery Africa 2025 will be held at the University of Ghana to highlight African-led drug discovery research focused on combating endemic infectious diseases. Spotlight on equity Gender equity: Antimalarials for pregnant women Women and girls are uniquely affected by malaria's health, economic and societal impacts. Malaria means a heightened risk of morbidity and mortality for pregnant women and girls and their newborns. This, in turn, contributes to keeping women and girls away from school and work, exacerbating gender inequalities in education and in the workplace, and ultimately intensifying gendered power imbalances in society. Read more about antimalarial drugs for pregnant women and how MMV works to remedy this with the Malaria in Mothers and Babies (MiMBa) strategy. Equitable partnerships: MMV's approach MMV’s equitable partnerships strategy aims to promote local ownership of R&D processes, expand clinical trial capacity and strengthen local research infrastructure, thus delivering sustainable impact. MMV successfully supports locally led partnerships (where endemic countries lead the decision-making) and co-creation partnerships (where decision-making is shared with partners) every step of the way – from conducting drug trials and bolstering clinical trial capacity, through working with pharmaceutical manufacturers, to generating evidence to steer policy change. MMV has identified four pillars of work to strengthen equitable partnerships in the Global South:1. People (sustainable capacity strengthening)2. Discovery, chemistry and manufacturing3. Clinical strategy4. Communication and advocacy 25 years of developing antimalarials
Add Comment